Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Immunoprecise Antibodies Ltd IPA

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.


NDAQ:IPA - Post by User

Comment by bigreturn11on Dec 31, 2020 11:17am
128 Views
Post# 32203419

RE:RE:Well this didn't go as planned

RE:RE:Well this didn't go as planned

I think we are left with excitement of a potential therapeutic that would be unmatched in the globe. Imagine positive phase I results at the end of January. Then heading into Phase II - if the Phase II results looks promising the opportunity at the current share price is significant. This is the excitement.....

In a couple short months this thing could go wayyy higher than previous all time highs.

wallpaper2 wrote: It went up the past 2-3 weeks on excitement and anticipation of a instant gap upwards in the share price on Dec.30th.
The next set of trials has yet to be announced but is supposed to start sometime in January?
I was told the trials will take at least 2 weeks to conduct and it will take a further 2 weeks to analyze them.
So what are we left with.......  disappointment and a falling share price until a big discovery and breakthrough. jmho

 

<< Previous
Bullboard Posts
Next >>